Jane Wasman
CIK 1352455 · President, Intl and GC · last filed 2026-05-19
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ACOR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
420 SAW MILL RIVER ROAD
ARDSLEY, NY 10502
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RIGL | Director | 18,250 | $50.05 | $913.4K | $0 | 9 | 2026-05-19 |
| SLS | Director | 92,900 | $12.23 | $1.14M | $33.8K | 11 | 2026-01-09 |
| ATHERSYS, INC / NEW (ATHX) Delisted | Director | 35,141 | $0.01 | $474 | $0 | 4 | 2023-01-11 |
| Acorda Therapeutics, Inc. (ACOR) Delisted | President, Intl and GC | 978 | $0.66 | $646 | -$7.69M | 63 | 2019-12-04 |
Recent Filings · Page 8 of 9
87 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2010-04-02 | Acorda Therapeutics, Inc. (ACOR) Delisted | Grant (A) | +20,000 | $0 | EDGAR |
| 2009-12-02 | Acorda Therapeutics, Inc. (ACOR) Delisted | Sell (S) | −5,000 | -$122.5K | EDGAR |
| 2009-03-04 | Acorda Therapeutics, Inc. (ACOR) Delisted | Grant (A) | +15,000 | $0 | EDGAR |
| 2008-12-03 | Acorda Therapeutics, Inc. (ACOR) Delisted | Sell (S) | −2,500 | -$40.0K | EDGAR |
| 2008-06-13 | Acorda Therapeutics, Inc. (ACOR) Delisted | Mixed | — | -$89.9K | EDGAR |
| 2008-05-12 | Acorda Therapeutics, Inc. (ACOR) Delisted | Sell (S) | −2,425 | -$46.3K | EDGAR |
| 2008-03-07 | Acorda Therapeutics, Inc. (ACOR) Delisted | Grant (A) | +15,000 | $0 | EDGAR |
| 2008-02-12 | Acorda Therapeutics, Inc. (ACOR) Delisted | Sell (S) | −2,425 | -$55.8K | EDGAR |
| 2008-01-24 | Acorda Therapeutics, Inc. (ACOR) Delisted | Sell (S) | −2,425 | -$55.2K | EDGAR |
| 2007-12-21 | Acorda Therapeutics, Inc. (ACOR) Delisted | Sell (S) | −2,425 | -$49.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.